PDS Biotechnology (PDSB)
(Delayed Data from NSDQ)
$3.82 USD
+0.09 (2.41%)
Updated May 3, 2024 04:00 PM ET
After-Market: $3.82 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Brokerage Reports
0 items in cart
PDS Biotechnology Corporation [PDSB]
Reports for Purchase
Showing records 1 - 20 ( 62 total )
Company: PDS Biotechnology Corporation
Industry: Medical - Biomedical and Genetics
2023 Results; A Data-Driven Pipeline Prioritization Puts Triple Combo Study Into the Spotlight
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: PDS Biotechnology Corporation
Industry: Medical - Biomedical and Genetics
3Q23 Results; Progress Continues Across the Pipeline; VERSATILE-003 Initiation Expected in 1Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: PDS Biotechnology Corporation
Industry: Medical - Biomedical and Genetics
NCI Triplet Study Delivers Real Nice Survival Update; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: PDS Biotechnology Corporation
Industry: Medical - Biomedical and Genetics
Biomarker Analysis Highlights PDS0101''s Immune Activating Properties in HNSCC
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: PDS Biotechnology Corporation
Industry: Medical - Biomedical and Genetics
Initial Phase 1/2 Data Showcase PDS0301''s MoA and Safety Profile in mPC
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: PDS Biotechnology Corporation
Industry: Medical - Biomedical and Genetics
Strong Phase 2 Update and KOL Event Highlight Promising Road For PDS0101
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: PDS Biotechnology Corporation
Industry: Medical - Biomedical and Genetics
Versamune Demonstrates Broad Applicability From Oncology to Infectious Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: PDS Biotechnology Corporation
Industry: Medical - Biomedical and Genetics
PDS0101 Could be Just What the Doctor Ordered For Investors and the Cancer Vaccine Space
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: PDS Biotechnology Corporation
Industry: Medical - Biomedical and Genetics
Gearing Up Against the Flu; PDS0202 Neutralizes Multiple Influenza Strains in Preclinical Studies
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: PDS Biotechnology Corporation
Industry: Medical - Biomedical and Genetics
2Q23 Results; Going Pivotal Soon; VERSATILE-003 Initiation Expected in 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: PDS Biotechnology Corporation
Industry: Medical - Biomedical and Genetics
PDS0101 Continues to Show Clinical Benefit in HNSCC as VERSATILE-002 Meets Key Clinical Efficacy Metric
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: PDS Biotechnology Corporation
Industry: Medical - Biomedical and Genetics
PDS0101 Continues to Impress at ASCO; Phase 3 Start Expected in 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: PDS Biotechnology Corporation
Industry: Medical - Biomedical and Genetics
VERSATILE-002 Survival Outcomes Shine as Study Matures; Full Presentation at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: PDS Biotechnology Corporation
Industry: Medical - Biomedical and Genetics
1Q23 Results; Immunotherapy Pipeline Advances; Updated VERSATILE-002 Data at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: PDS Biotechnology Corporation
Industry: Medical - Biomedical and Genetics
KOLs Highlight Differentiated IL-12 Approach and PDS0301
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: PDS Biotechnology Corporation
Industry: Medical - Biomedical and Genetics
PDS0101 Ready to Take Next Step; VERSATILE-003 Phase 3 Registrational Study Poised to Begin 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: PDS Biotechnology Corporation
Industry: Medical - Biomedical and Genetics
2022 Results; PDS0101 Clinical Development Forges Ahead
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: PDS Biotechnology Corporation
Industry: Medical - Biomedical and Genetics
Positive FDA Meeting Provides Next Layer of Visibility for PDS0101; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: PDS Biotechnology Corporation
Industry: Medical - Biomedical and Genetics
Pipeline Toolbox Expands; PDS0301 Joins the Pipeline; Target Increased to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: PDS Biotechnology Corporation
Industry: Medical - Biomedical and Genetics
PDS0101 Expanded Interim Data Continue to Support Durability of Triple Combo Therapy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J